Metabolic dysfunction-associated steatohepatitis — liver fat with inflammation and cell injury that can progress to fibrosis and cirrhosis. Formerly called NASH.

Why are liver trials so difficult?

The endpoints require biopsy and histological scoring, which is a pathologist's judgement with documented inter-observer variability.

Are the endpoints clinical outcomes?

No. They are histological surrogates for progression to cirrhosis and death, which no trial can practically follow to completion.

GLP-1 & Incretin Science

Semaglutide and Liver Disease: What ESSENCE Tested

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

ESSENCE is a Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis, registered as NCT04822181 with 1,205 participants. Sanyal and colleagues published results in the New England Journal of Medicine in June 2025.

Key facts

Trial: ESSENCE, NCT04822181
Phase: 3
Enrolment: 1,205
Status: Active, not recruiting
Condition: MASH — formerly NASH
Published: NEJM 2025 (PMID 40305708)
Design paper: Newsome 2024 (PMID 39412509)

What MASH is

Metabolic dysfunction-associated steatohepatitis: fat accumulation in the liver accompanied by inflammation and liver cell injury, which can progress to fibrosis and cirrhosis. It was called NASH — non-alcoholic steatohepatitis — until a renaming that shifted the emphasis from what the condition is not to what drives it. The trial registration still carries the older name.

Why an incretin was an obvious candidate

MASH sits downstream of the same metabolic disturbance that produces obesity and type 2 diabetes. A drug that substantially reduces body weight and improves glycaemic control is acting on the upstream drivers, so the hypothesis is mechanistically coherent rather than opportunistic. Whether the benefit is weight reduction alone or something more direct is a separate and unsettled question.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why liver trials are unusually difficult

The endpoints require liver biopsy. Histological scoring of inflammation, ballooning and fibrosis is a pathologist's judgement, not a machine reading, and inter-observer variability is well documented. Trials therefore need central reading, and even then the endpoint is noisier than a blood pressure or an HbA1c. This is a substantial reason MASH drug development has been slow.

What the trial reports on

Resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis — the two histological endpoints this field has converged on. Both are surrogates for what actually matters, which is progression to cirrhosis, liver failure and death over timescales no trial can practically cover.

The regulatory consequence of that

Because the endpoints are surrogates, approvals in this area have come through accelerated pathways that require confirmatory evidence afterwards. That is a genuinely different kind of approval from one granted on clinical outcomes, and the distinction is rarely made in coverage.

What it does not concern

Research material. Semaglutide is a licensed medicine, ESSENCE is a registered trial conducted under clinical supervision, and nothing supplied here is semaglutide, related to it, or an alternative to any liver treatment.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is MASH?: Metabolic dysfunction-associated steatohepatitis — liver fat with inflammation and cell injury that can progress to fibrosis and cirrhosis. Formerly called NASH.
Why are liver trials so difficult?: The endpoints require biopsy and histological scoring, which is a pathologist's judgement with documented inter-observer variability.
Are the endpoints clinical outcomes?: No. They are histological surrogates for progression to cirrhosis and death, which no trial can practically follow to completion.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum